Preclinical researches showed that CD4+ T cells changed their dominant subsets from Th1 in the early stages to Treg and Th17 cells in the late stages of the cancer progression (42), interestingly, oligometastatic disease was proposed as an intermediate state between localized and systemically metastasized disease. This evidence concerns the gene CD4 and cancer.